Evidence map›Paper›PMID 38936974›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2024

Prostate-Specific Membrane Antigen-Targeted Imaging and Its Correlation with HOXB13 Expression.

Duminduni Hewa Angappulige, Nimrod S Barashi, Nicholas Pickersgill, Cody Weimholt, Jingqin Luo, Ghazal Shadmani, Ziad Tarcha, Sampanna Rayamajhi, Nupam P Mahajan, Gerald L Andriole and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Dual-tracer PET/CT with [European journal of nuclear medicine and molecular imaging · 2026
    Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Duminduni Hewa AngappuligeDivision of Urologic Surgery, Department of Surgery, Washington University in St. Louis, St. Louis, Missouri.
Nimrod S BarashiDivision of Urologic Surgery, Department of Surgery, Washington University in St. Louis, St. Louis, Missouri.
Nicholas PickersgillDivision of Urologic Surgery, Department of Surgery, Washington University in St. Louis, St. Louis, Missouri.
Cody WeimholtDepartment of Pathology and Immunology, Washington University in St. Louis, St. Louis, Missouri.
Jingqin LuoDivision of Public Health, Department of Surgery, Washington University in St. Louis, St. Louis, Missouri.
Ghazal ShadmaniDivision of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, Missouri.
Ziad TarchaDivision of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, Missouri.
Sampanna RayamajhiDivision of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, Missouri.
Nupam P MahajanDivision of Urologic Surgery, Department of Surgery, Washington University in St. Louis, St. Louis, Missouri.
Gerald L AndrioleDivision of Urologic Surgery, Department of Surgery, Washington University in St. Louis, St. Louis, Missouri.
Barry A SiegelAlvin J. Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri; and.
Eric H KimDivision of Urologic Surgery, Department of Surgery, Washington University in St. Louis, St. Louis, Missouri.
Kiran MahajanDivision of Urologic Surgery, Department of Surgery, Washington University in St. Louis, St. Louis, Missouri; kiranm@wustl.edu.

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
Diffusion Histology Imaging: A Clinical Tool to Non-Invasively Diagnose and Manage Prostate CancerR01CA258690 · NCI · WASHINGTON UNIVERSITY · PI Joseph Edward Ippolito, Michael Hiroshi Johnson · 2022 to 2026
$2.7M
NCI NIH HHS P30 CA091842NCI NIH HHS R01 CA258690
6 · The paper itself

Abstract

Homeobox 13 (HOXB13) is an oncogenic transcription factor that directly regulates expression of folate hydrolase 1, which encodes prostate-specific membrane antigen (PSMA). HOXB13 is expressed in primary and metastatic prostate cancers (PCs) and promotes androgen-independent PC growth. Since HOXB13 promotes resistance to androgen receptor (AR)-targeted therapies and regulates the expression of folate hydrolase 1, we investigated whether SUVs on PSMA PET would correlate with HOXB13 expression.

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIHomeodomain ProteinsPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedGene Expression Regulation, NeoplasticHumansMaleMiddle AgedAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIHomeodomain ProteinsHOXB13 protein, humanandrogen receptorHOXB13metastasisprostate cancerPSMAPSMA PET

Identifiers

PMID38936974
PMCPMC11294063

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.